Trial · NCT03469349
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Initial Claudication Distance (ICD) at Week 12 | Placebo | 21.99 | Standard Error 9.286 | percent change | |
| Percent Change From Baseline in Initial Claudication Distance (ICD) at Week 12 | Actovegin 1200 mg | 51.17 | Standard Error 9.187 | percent change | |
| Percent Change From Baseline in ICD at Weeks 2 and 24 | Placebo | Week 2 | 6.58 | Standard Error 8.131 | percent change |
| Percent Change From Baseline in ICD at Weeks 2 and 24 | Actovegin 1200 mg | Week 2 | 22.45 | Standard Error 7.981 | percent change |
| Percent Change From Baseline in ICD at Weeks 2 and 24 | Placebo | Week 24 | 25.12 | Standard Error 10.665 | percent change |
| Percent Change From Baseline in ICD at Weeks 2 and 24 | Actovegin 1200 mg | Week 24 | 60.63 | Standard Error 10.614 | percent change |
| Absolute Change From Baseline in Absolute Claudication Distance (ACD) at Weeks 2, 12 and 24 | Placebo | Baseline | 134.5 | Standard Deviation 58.84 | meter |
| Absolute Change From Baseline in Absolute Claudication Distance (ACD) at Weeks 2, 12 and 24 | Actovegin 1200 mg | Baseline | 137.1 | Standard Deviation 72.76 | meter |
| Absolute Change From Baseline in Absolute Claudication Distance (ACD) at Weeks 2, 12 and 24 | Placebo | Change at Week 2 | 17.61 | Standard Deviation 30.781 | meter |
| Absolute Change From Baseline in Absolute Claudication Distance (ACD) at Weeks 2, 12 and 24 | Actovegin 1200 mg | Change at Week 2 | 46.28 | Standard Deviation 179.356 | meter |
| Absolute Change From Baseline in Absolute Claudication Distance (ACD) at Weeks 2, 12 and 24 | Placebo | Change at Week 12 | 30.05 | Standard Deviation 50.530 | meter |
| Absolute Change From Baseline in Absolute Claudication Distance (ACD) at Weeks 2, 12 and 24 | Actovegin 1200 mg | Change at Week 12 | 75.51 | Standard Deviation 190.808 | meter |
| Absolute Change From Baseline in Absolute Claudication Distance (ACD) at Weeks 2, 12 and 24 | Placebo | Change at Week 24 | 36.37 | Standard Deviation 71.834 | meter |
| Absolute Change From Baseline in Absolute Claudication Distance (ACD) at Weeks 2, 12 and 24 | Actovegin 1200 mg | Change at Week 24 | 86.47 | Standard Deviation 227.491 | meter |
| Percentage of Participants With Rest Pain at Weeks 12 and 24 | Placebo | Week 12 | 0 | percentage of participants | |
| Percentage of Participants With Rest Pain at Weeks 12 and 24 | Actovegin 1200 mg | Week 12 | 0.6 | percentage of participants | |
| Percentage of Participants With Rest Pain at Weeks 12 and 24 | Placebo | Week 24 | 1.1 | percentage of participants | |
| Percentage of Participants With Rest Pain at Weeks 12 and 24 | Actovegin 1200 mg | Week 24 | 0.6 | percentage of participants | |
| Percentage of Participants With Revascularization Procedures at Week 24 | Placebo | 0.0 | percentage of participants | ||
| Percentage of Participants With Revascularization Procedures at Week 24 | Actovegin 1200 mg | 1.1 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03469349/results